english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2021 > The Prescrire Drug Awards for 2021 > 2021 Drug Awards > Jorveza° (budesonide orodispersible tablets): cited as Noteworthy at the 2021 Prescrire Drug Awards

The Prescrire Awards for 2021

The Prescrire Drug Awards for 2021

The Prescrire Drug Awards for 2021
Jorveza° (budesonide orodispersible tablets): cited as Noteworthy at the 2021 Prescrire Drug Awards

Le Palmarès des Médicaments Drugs deemed Noteworthy provide a modest improvement in patient care.

• JORVEZA° (budesonide orodispersible tablets) – Dr. Falk Pharma

In eosinophilic oesophagitis in adults (Prescrire Int n° 234)

Budesonide orodispersible tablets in eosinophilic oesophagitis: symptom relief in about half of patients.

Eosinophilic oesophagitis is a chronic immune-mediated disease. Its symptoms, such as dysphagia, cause feeding difficulties that can greatly affect the patient's daily life. Potential complications are: complete blockage of the oesophagus with food, requiring endoscopy to clear the obstruction; more rarely, oesophageal rupture or perforation; and in the longer term, fibrosis of the oesophagus.

In two trials in just over 200 patients, about an additional 50% of patients in the groups treated with budesonide orodispersible tablets (Jorveza°) obtained relief from the symptoms of dysphagia as compared with the placebo groups.

The main adverse effects of budesonide orodispersible tablets are local candidiasis and the systemic adverse effects of corticosteroids, especially with prolonged use. The availability of orodispersible tablets, backed up by the assurances that marketing authorisation provides, is a welcome development in this situation, in which forms of budesonide intended for inhalation were sometimes used off-label.

The therapeutic advance provided by these orodispersible tablets warrants a place amongst this year's Noteworthy drugs. It is a shame, however, that continuous treatment was not compared with an intermittent treatment strategy in which budesonide would only be taken if symptoms recur, thus reducing the likelihood of experiencing the drug's adverse effects.

A Pilule d'Or (Golden Pill) is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations. Drugs deemed "Noteworthy" provide a modest improvement in patient care.
SEE: > About the Prescrire Drug Awards for 2021

Le Palmarès de l'information
> The Prescrire Drug Awards for 2021


Download the full article:
Télécharger
 FREE  "The Prescrire Awards for 2021" Prescrire International 2022; 31 (235): 79-82. (pdf, free)

 

Back to "The Prescrire Awards for 2021">

©Prescrire February 2022
 Share Share on Facebook Share on Twitter

Filet

Enjoy full access to Prescrire International, and support independent information